68Ga-PSMA配体PET/CT分子显像发现甲状腺滤泡状腺瘤肿瘤新生血管内皮细胞表达PSMA
本文报告一例65岁去势抵抗性转移性前列腺癌男性患者,因疾病再分期接受68Ga-PSMA配体PET/CT,甲状腺病灶出现PSMA配体摄取,超声疑为甲状腺恶性肿瘤;后续切除及组织病理学分析显示为甲状腺滤泡状腺瘤,PSMA表达于肿瘤新生血管内皮细胞,而非甲状腺上皮细胞。作者指出,恶性与良性甲状腺肿瘤均可能显示PSMA表达,应予以认识以避免误判。
要点
- 68Ga-PSMA配体PET/CT示甲状腺病灶摄取,超声疑甲状腺恶性。
- 切除后病理为甲状腺滤泡状腺瘤,PSMA表达于肿瘤新生血管内皮细胞。
- 甲状腺上皮细胞未见PSMA表达,良恶性甲状腺肿瘤均可有PSMA表达。
核心结论
- 甲状腺滤泡状腺瘤的新生血管内皮细胞可表达PSMA,良恶性甲状腺肿瘤均可能显示PSMA表达,应认识以避免误判。
研究设计与样本
- 本文为病例报告,报告一例65岁去势抵抗性转移性前列腺癌男性患者,因疾病再分期接受68Ga-PSMA配体PET/CT检查。
主要发现
- 68Ga-PSMA配体PET/CT见甲状腺病灶PSMA配体蓄积,补充超声疑为甲状腺恶性肿瘤。
- 后续切除及组织病理学分析显示为甲状腺滤泡状腺瘤,PSMA表达见于肿瘤新生血管内皮细胞,甲状腺上皮细胞未见表达。
临床怎么用
- 作者指出,应认识到恶性与良性甲状腺肿瘤均可能显示PSMA表达,以避免误判。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prostate-specific membrane antigen (PSMA) is expressed by both prostate cancer and other neoplasms. We report the case of a 65-year-old man with castration-resistant metastatic prostate cancer who underwent Ga-PSMA ligand PET/CT for restaging of disease. Ga-PSMA ligand accumulation was noted in a thyroid lesion, suspicious for thyroid malignancy on complementary ultrasound. Subsequent resection and histopathological analysis showed follicular thyroid adenoma with PSMA expression in tumor neovasculature endothelial cells, but not in thyroid epithelial cells. It is important to be aware that both malignant and benign thyroid neoplasms may show PSMA expression to avoid misinterpretation.
引用
- Derlin T, Kreipe HH, Schumacher U, et al. PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68Ga-PSMA Ligand PET/CT. Clin Nucl Med. 2017. PMID: 27997422. doi:10.1097/RLU.0000000000001487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。